Skip to main content

Table 4 Gene mutation detection in urine supernatant and urine sediments

From: Detection of bladder cancer using urinary cell-free DNA and cellular DNA

Supernatant

Cancer (n = 92)

Control (n = 33)

PPV (%)

NPV (%)

n

Sensitivity (%)

n

Specificity (%)

TERT

42

46

0

100

100

40

FGFR3

35

38

0

100

100

37

TP53

27

29

0

100

100

34

PIK3CA

24

26

0

100

100

33

KRAS

15

16

0

100

100

30

CDKN2A

9

10

0

100

100

28

HRAS

9

10

0

100

100

28

AKT1

7

8

0

100

100

28

ERBB2

6

7

0

100

100

28

ACTB

4

4

1

97

80

27

BRAF

3

3

1

97

75

26

KDM6A

3

3

1

97

75

26

EGFR

2

2

0

100

100

27

CTNNB1

1

1

2

94

33

25

CUL1

1

1

0

100

100

27

FBXW7

1

1

0

100

100

27

PTEN

1

1

0

100

100

27

STAG2

1

1

0

100

100

27

U2AF1

1

1

1

97

50

26

Sediment

Cancer (n = 92)

Control (n = 33)

PPV (%)

NPV (%)

n

Sensitivity (%)

n

Specificity (%)

TERT

44

48

0

100

100

41

FGFR3

34

37

1

97

97

36

PIK3CA

22

24

1

97

96

31

TP53

20

22

6

82

77

27

KRAS

14

15

0

100

100

30

HRAS

13

14

0

100

100

29

CDKN2A

9

10

0

100

100

28

AKT1

7

8

0

100

100

28

ERBB2

6

7

0

100

100

28

BRAF

3

3

0

100

100

27

KDM6A

2

2

0

100

100

27

CTNNB1

1

1

0

100

100

27

FBXW7

1

1

0

100

100

27

PTEN

1

1

0

100

100

27

STAG2

1

1

0

100

100

27

  1. n: The number of samples in which the gene mutation was detected